Supplementary Tables S1-S10 from ACTA2 Expression Predicts Survival and Is Associated with Response to Immune Checkpoint Inhibitors in Gastric Cancer

Supplementary Table 1. Univariable associations of the multivariable Cox proportional hazards model in the Yonsei cohort.Supplementary Table 2. Clinical characteristics of patients in the pooled validation cohort.Supplementary Table 3. Univariable associations of the multivariable Cox proportional hazards model of the pooled validation cohort.Supplementary Table 4. Univariable Cox proportional hazards regression of the association of individual genes of the 32-gene signature and their association with overall survival in the Yonsei cohort.Supplementary Table 5. Univariable Cox proportional hazards regression of the association of individual genes of the 32-gene signature and their association with overall survival in the pooled cohort.Supplementary Table 6. Multivariable analysis of the pooled cohort including microsatellite stability status.Supplementary Table 7. Multivariable analysis of the association of ACTA2 expression with recurrence-free survival in the pooled cohort.Supplementary Table 8. Clinical characteristics of patients treated with immune checkpoint inhibitors.Supplementary Table 9. ACTA2 expression in cells analyzed by single nuclear RNA sequencing cohort.Supplementary Table 10. Characteristics of patients analzyed by digital spatial transcriptomics.